Health Care Cost

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Cell therapy and targeted agents are transforming blood cancer outcomes, but infrastructure, funding, and workforce gaps are limiting who can access them.

Arshad Khanani, MD, weighs Wnt- and Tie2-targeting agents against gene therapy and makes the case for payers to look past price to long-term value.

New hypertension drugs cost over $800,000 per QALY vs generics, well above cost-effectiveness limits, ICER's draft report finds.

Eli Lilly's investigational triple agonist is already fueling gray-market sales and a $1 trillion valuation narrative ahead of its 2027 FDA filing.

Rising premiums and out-of-pocket costs top Americans' health care concerns across party lines, a Commonwealth Fund survey finds.

Although topical delgocitinib matched injectable dupilumab for CHE, real-world adherence could determine whether that holds outside clinical trials.

Employers with complete claims data access deploy more cost-containment strategies as health care costs rise and employers seek greater PBM transparency.

Taking effect in October 2026, the final rule will end federal Medicaid and CHIP funding for gender-affirming care for transgender minors.

Arshad Khanani, MD, explains why gene therapy for wet age-related macular degeneration (AMD) is close to becoming a real-world option for the masses.

July AJMC author Anuraag R. Kansal, PhD, explains how metastatic cancer diagnoses drive Medicaid spending and why earlier screening could lower costs.

MASLD was linked to higher odds of EoE and reflux-related diseases, suggesting metabolic dysfunction may contribute to esophageal disease.

CANN says the revised pilot reflects stakeholder input and aims to address accountability challenges in the more than $100 billion 340B program.

Peter Forsberg, MD, discusses referral pathways, payer barriers, and expanding access to CAR T-cell and bispecific therapies.

The Pharmacy Compounding Advisory Committee narrowly recommended BPC-157, KPV, TB-500, MOTS-c, Semax, and epitalon for the 503A Bulks List.

A federal judge heard arguments over whether CMS unlawfully narrowed the Medicaid work requirement exemption for medically frail beneficiaries.

Panel experts at Nashville’s IVBM event discussed matching cancer therapy intensity to disease, easing access barriers, and reforming pharmacy/PBM policies.

A July AJMC study found metastatic cancer diagnoses significantly increase Medicaid spending, highlighting the potential budget benefits of earlier detection.

June delivered 5 FDA firsts; FDA panel weighs peptide access; dermatology absorbs PA costs; Trump sets tariff timeline; digital QI trims LDL-C.

The Pharmacy Compounding Advisory Committee meets July 23-24 to discuss whether pharmacies may dispense BPC-157, TB-500, and 5 other peptides.

Trump said imported generic drugs will face no tariff for 2 years starting August 1, then a 100% rate in 2028 and 200% in 2029, extending his trade fight to the drugs most Americans actually take.

Diagnostic delays and access barriers continue to affect patients with MS, especially in under-resourced areas, World Brain Day highlights.

Kanita Bourne, LCSW, discusses how implicit bias, missed depression signs, and expanded doula access are shaping Black maternal health outcomes.

Paul Hahn, MD, says access and reimbursement, not innovation, are retina care’s biggest barriers and outlines where the field is headed next.

Existing rebates and manufacturers' gaming risk may limit these gains.